Do-Coop Technologies introduces Neowater - Solubilisation Service

Do-Coop Technologies, a privately held corporation based in Israel, has launched a service that solvates customers' hydrophobic, insoluble molecules and drugs using Do-Coop's proprietary Neowater technology, improving solubility and bioavailability.

Neowater is an enabling technology that is based on breakthrough water-based nanotechnology. Unlike traditional, dry nanotechnology, which focuses on a nanoparticle end product, Neowater builds upon the unique properties of nanoparticles to modify the physical properties of water molecules around them.

Each nanoparticle within Neowater, with its huge surface, creates an effect known as the 'surface effect', and in turn organises the water molecules surrounding it. This is similar to the surface effect of organelles within living cells. Both the organelles and the nanoparticles use this unique mechanism to create intracellular water. While the former is within cells and organs and cannot be harnessed nor used in a lab bench, the latter, which is branded as Neowater, can.

This technology, developed in Israel, produces water whose physical properties mimic that of intracellular water using inorganic, insoluble crystals introduced in water in a patented process. Neowater, with its stable system of largely hydrated nanoparticles, reduces the entropy of aqueous solutions. In addition, by design, it exhibits both hydrophilic and hydrophobic properties.

Neowater technology dramatically enhances the stability and bioavailability of compounds that are difficult-to-solvate, or that can be dissolved with organic solvents but then exhibit poor bioavailability or have toxicity-related issues.

'We are launching our Neowater - Solubilisation Service in response to requests from customers for us to help them overcome a very painful technological barrier and allow them to solvate their difficult-to-solvate, hydrophobic compounds without organic solvents,' said Eran Gabbai, founder, president and cto of Do-Coop Technologies, and the inventor of Neowater technology.

'We have designed the new Solubilisation Service in such a way that it is simple to use, limiting the amount of information a customer needs to disclose to us, and providing a straightforward solution for customers to validate in their own labs.

Neowater is nontoxic, environmentally friendly, inexpensive, and can easily be integrated into existing and new drugs and allow for IPR extension. We anticipate that with this service launch many more biotech and pharma companies will be able to validate the performance of Neowater-solvated compounds in their own laboratory tests, and then return to us to license this unique capability,' he added.